Posted by Michael Wonder on 16 Dec 2021
AVT02, Alvotech’s biosimilar to high concentration formulation of adalimumab (Humira) approved for use in European Union
15 December 2021 - Alvotech received approval for AVT02 (100 mg/mL), the company’s high concentration biosimilar to Humira (adalimumab), from the European Commission on 15 November.
The centralised marketing authorisation in the European Union follows the recommendation of the CHMP for approval of AVT02 in September, and includes all EU Member States, as well as countries in the European Economic Area, Iceland, Liechtenstein and Norway.
